Litcius/Paper detail

Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti–neutrophil cytoplasmic antibody–associated vasculitis

Sam Kant, Antoine Azar, Duvuru Geetha

2021Kidney International16 citationsDOIOpen Access PDF

Topics & Concepts

RituximabMedicineVasculitisImmunologyAntibodyCoronavirus disease 2019 (COVID-19)VirologyAnti-neutrophil cytoplasmic antibodySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PathologyInfectious disease (medical specialty)DiseaseHeparin-Induced Thrombocytopenia and ThrombosisVasculitis and related conditionsDrug-Induced Adverse Reactions
Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti–neutrophil cytoplasmic antibody–associated vasculitis | Litcius